Research Ins]i[ghts Cardiac Safety Symposium 2021

Nanion symposium 1200x627 01

Now Available On-Demand

Meeting Venue: Interactive Virtual Event 

Research Ins]i[ghts: Cardiac Safety Symposium 2021

Don't miss this 2-day interactive online event and Current Challenges in Safety Pharmacology and Cardiac Physiology, in-silico modelling and Best Practices and Evolvements of Safety Pharmacology Methods.

Date and time:
Start: Wednesday, May 19th (Beginning at 1PM CEST, 7AM EDT )  
End: Thursday, May 20th (Beginning at 1PM CEST, 7AM EDT )  


Yasunari Kanda,
PhD, Division head, National Institute of Health Sciences Japan
Title: Current status and future perspectives in cardiac safety assessment using human iPSC technology
Day 1 [1:10 PM - 2 PM CEST]

Michael K. Pugsley, PhD, FBPhS, DSP, Cytokinetics
Title: A 20 Year Journey through the Continuously Evolving Role of Safety Pharmacology in Drug Safety Evaluation
Day 2 [3:10 PM - 4 PM CEST]

Access the full agenda of the Meeting below:


Additional presentations by:

Ralf Kettenhofen, PhD, Senior Scientist and Business Development, Fraunhofer Institute for Biomedical Engineering IBMT
Title: From iPSC Banking to Drug Development & Cardiac Safety 
Day 1 [2 PM - 2:30 PM CEST]

Bettina Lickiss, PhD, Scientific Communications Manager, innoVitro GmbH
Title: Advanced cardiac contractility assessment with integrated mechanical and optical stimulation of human iPSC-derived cardiomyocytes
Day 1 [2:45 PM - 3:10 PM CEST]

Khuram Chaudhary, PhD, Scientific Director, GlaxoSmithKline
Title: In vitro cardiac safety pharmacology- considerations beyond hERG
Day 1 [3:10 PM - 3:35 PM CEST]

Ravi Vaidyanathan, PhD, Product Manager - Cardiac - FUJIFILM Cellular Dynamics, Inc.
Title: Predictive and Physiologically Relevant 3D Tri-culture Cardiac Microtissue with iCell® Cardiomyocytes, Endothelial Cells and Primary Cardiac Fibroblast
Day 1 [3:35 PM - 3:45 PM CEST]

Stephen Jenkinson,
PhD, Director of In Vitro Pharmacology, Pfizer Inc.
Title: The use of stem cell cardiomyocyte models in predicting clinical cardiac endpoints
Day 1 [3:45 PM - 4:10 PM CEST]

Jin Chang, BD & Alliance Manager, NEXEL Co. Ltd
Title: Challenging our understanding of iPSC-based cardiac safety with physiologically relevant and assay-ready cell culture media
Day 1 [4:10 PM - 4:20 PM CEST]

Adam Hill,
PhD,  Head Computational Cardiology, Victor Chang Cardiac Research Institute
Title: An automated, cloud-based platform for quality control, data analysis and risk prediction of inherited and drug-induced arrhythmias
Day 2 [1:05 PM - 1:30 PM CEST]

Jessica Veenman-Koepke, Scientist & Project leader at Ncardia
Title: Multi-parametric Drug Safety Assessment in Bioreactor-produced Ncyte hiPSC-derived Cardiomyocytes
Day 2 [1:30 PM - 1:40 PM CEST] 

Gary Mirams,
 Professor of Mathematical Physiology, University of Nottingham
Title: Examining temperature dependence of hERG1a gating
Day 2 [1:40 PM - 2:05 PM CEST] 

Teun de Boer, Associate Professor, Dept. of Medical Physiology, UMC Utrecht
Title: Building hybrid biological-digital twins of cardiomyocytes using dynamic clamping
Day 2 [2:05 PM - 2:30 PM CEST]

James Kramer,
Principal Scientist, Charles River Laboratories
Title: ICH S7B Q&As - Best Practices for Ion Channel Assays
Day 2 [2:45 PM - 3:10 PM CEST]

Al George, Professor and Chair of Pharmacology, Northwestern University
Title: Automated Patch Clamp to Assess Sodium Channel Blocker Effects on hiPSC-derived Cardiomyocytes
Day 2 [4:00 PM - 4:25 PM CEST]

Now Available On-Demand - Watch Now

Access the Q&A from the presentations here

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.